Title:
Global Vaccine Development for World Health Symposium/FDA, EMEA, Emerging Regions, NGO, and Industry Perspectives
Date(s) And Time(s):
Nov 3 2009 8:00AM - Nov 4 2009 5:00PM
Location:
Marriott Bethesda North Hotel
5701 Marinelli Road
North Bethesda, MD 20852-2785
Interest Area(s):
Clinical Safety/Pharmacovigilance, Clinical Research, Quality Assurance/Quality Control, Regulatory Affairs, Statistics
Overview:
Regulatory Pathways of Vaccines for Global Diseases
CONFERENCE OVERVIEW
This global vaccine development symposium will address the expanding need for discussion on regulatory guidelines for the development of vaccines for infectious diseases. Professionals from industry and worldwide regulatory agencies will present the current challenges and solutions around this critical field of global healthcare. Ethical and cultural perspectives will also be presented by members of organizations such as World Health Organization (WHO), The Bill and Melinda Gates Foundation, International Vaccine Initiative (IVI), Developing Countries Vaccine Regulatory Network (DCVRN), and BIO Ventures for Global Health (BVGH). In addition, specific focus will be given to the WHO prequalification process and the FDAAA voucher program as they relate to global vaccine
development for world health.
OBJECTIVES
· Compare the role of the United States (FDA) and European (EMEA) regulatory authorities in facilitating the regulation of vaccines against global infectious diseases
· Understand the impact of the WHO’s prequalification/procurement process on providing access to vaccines for global health
· Review the voucher process established under FDAAA to create greater incentives for developing vaccines for global infectious diseases, and the economic and vaccine development implications of this process
· Discuss the ethical challenges in assessing vaccines for global infectious diseases
· Elucidate perspectives from industry, NGOs and developing countries on the regulatory challenges to global vaccine development
Learning Objectives:
At the conclusion of this meeting, participants should be able to:
· Compare the role of the United States (FDA) and European (EMEA) regulatory authorities in facilitating the regulation of vaccines against global infectious diseases;
· Describe the impact of the WHO’s prequalification / procurement process on providing access to vaccines for global health;
· Review the voucher process established under FDAAA to create greater incentives for developing vaccines for global infectious diseases, and the economic and vaccine development implications
· of this process;
· Discuss the ethical challenges in assessing vaccines for global infectious diseases;
· Recognize perspectives from industry, NGOs and developing countries on the regulatory challenges for global vaccine development.
Target Audience:
This program will benefit individuals involved in
· Clinical Research and Development
· Clinical Safety/Pharmacoepidemiology/Pharmacovigilance
· Pharmacology
· Quality of Life/Health Economics/Outcomes Research
· Quality Control/Quality Assurance
· Regulatory Affairs/Policy/Drug or Device Approval/GRP
· Research and Development/Strategic Issues
· Pharmaceutical Senior Executive Level/Business Leaders
Event Code:
09023
Contact Information:
Attendees may visit the tabletop exhibits during the event and during receptions (if applicable).
Event information: Contact Jo Ann Boileau at the DIA office by telephone +1-215-442-6175, fax +1-215-293-5940 or email JoAnn.Boileau@diahome.org.
Tabletop exhibit information: Contact Shannon Lewis, Exhibits Associate, at the DIA office by telephone +1-215-442-6149, fax +1-215-442-6199 or email Shannon. Lewis@diahome.org. For tabletop exhibit space, please check the box below.